Cardiovascular diseases Trials in New York, United States
Conditions / Cardiovascular diseases / New York, United States
Clinical trials for Cardiovascular diseases investigate a range of treatment strategies and patient populations.
93 total trials for this combination
Showing top 10 of 93 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07064473 | EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | RECRUITING | — |
| NCT05803421 | A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk | COMPLETED | — |
| NCT03626688 | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | COMPLETED | — |
| NCT03626688 | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | COMPLETED | — |
| NCT00000620 | Action to Control Cardiovascular Risk in Diabetes (ACCORD) | COMPLETED | PHASE3 |
| NCT03683186 | A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | ENROLLING_BY_INVITATION | PHASE3 |
| NCT03626688 | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | COMPLETED | — |
| NCT01471522 | International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) | COMPLETED | NA |
| NCT07064473 | EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | RECRUITING | — |
| NCT05820295 | Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coordination | COMPLETED | NA |